Premium
Traceable Nano‐Biohybrid Complexes by One‐Step Synthesis as CRISPR‐Chem Vectors for Neurodegenerative Diseases Synergistic Treatment
Author(s) -
Shen Jie,
Lu Zhiguo,
Wang Jianze,
Hao Qiulian,
Ji Weihong,
Wu Yanyue,
Peng Huan,
Zhao Ruichen,
Yang Jun,
Li Yan,
Shi Zhuyan,
Zhang Xin
Publication year - 2021
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.202101993
Subject(s) - crispr , cas9 , genome editing , nanotechnology , computational biology , genetic enhancement , regeneration (biology) , materials science , neuroscience , biology , gene , microbiology and biotechnology , biochemistry
Abnormal protein aggregations are essential pathological features of neurodegenerative diseases. Eliminating while inhibiting the regeneration of these protein aggregates is considered an effective treatment strategy. Herein, the CRISPR/Cas9 gene‐editing tool is employed to inhibit the regeneration of disease‐related proteins, while chemical drugs are applied to eliminate the proteins that are produced. To efficiently deliver CRISPR‐chem drugs into brain lesions, traceable nano‐biohybrid complexes (F‐TBIO) are constructed by one‐step synthesis and CRISPR/Cas9 plasmids (CF‐TBIO) are loaded in a controllable manner. CF‐TBIO can knock out the BACE1 gene and reduce the burden of amyloid‐β, and thereby significantly improve the cognitive abilities of 2xTg‐AD mice. In particular, by prolonging the dosing interval, the pathological damage and behavioral abilities of 2xTg‐AD mice are still significantly improved. During the therapeutic process, CF‐TBIO with a high relaxation rate provides accurate imaging signals in the complex brain physiological environment. The finding shows that CF‐TBIO has great potential to serve as a CRISPR‐chem drug‐delivery platform for neurodegenerative diseases therapy.